2026 Realistic CCDM 100% Pass Guaranteed Download Exam Q&A
Accurate CCDM Answers 365 Days Free Updates
NEW QUESTION # 44
What are the first logical specifications that need approval when building an efficient EDC database?
- A. eCRF Guidelines
- B. eCRF Fields
- C. Edit Check Logic
- D. Metric Reports
Answer: B
Explanation:
In the EDC database build process, the first logical specifications that require approval are the electronic Case Report Form (eCRF) fields.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and Build), eCRF field specifications define what data elements are collected, their data types, permitted values, field lengths, and any associated metadata. Approval of these specifications forms the foundation for subsequent design components such as edit check programming, query management rules, and data validation logic.
Edit checks (B) are developed only after fields and structures are finalized.
Metric reports (C) and eCRF guidelines (D) are downstream documentation or tools, not logical specifications required at the build start.
Therefore, option A (eCRF fields) is correct, as their approval marks the first formal milestone in the EDC system development life cycle.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 4.2 - Logical Design and eCRF Field Specifications ICH E6(R2) GCP, Section 5.5.3 - System Design and Validation Documentation FDA 21 CFR Part 11 - System Validation and Documentation Controls
NEW QUESTION # 45
A Data Manager is establishing a timeline for database lock for a 100-person study where the data have been maintained almost all clean throughout the study. All data from external labs have been received and reconciled. Which is the best estimate of the amount of time needed to lock the database after Last Patient Last Visit?
- A. A few days
- B. A few weeks
- C. A few months
- D. A few hours
Answer: A
Explanation:
For a well-maintained 100-subject study with ongoing data cleaning and completed reconciliations, the database lock process typically takes a few days after the Last Patient Last Visit (LPLV).
According to the GCDMP (Chapter: Database Lock and Archiving), the duration of the lock process depends on the level of data cleanliness at LPLV. If the study team has conducted continuous data cleaning, query resolution, and external data reconciliation throughout the trial, then the final lock steps (e.g., final data review, documentation, and approvals) can be completed in 2-5 days.
However, if significant cleaning or reconciliation remains outstanding, lock may take several weeks. Since the question states that data are "maintained almost all clean," Option B - a few days - is the appropriate estimate.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 6.2 - Database Lock Preparation and Timelines ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Quality and Lock Procedures FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Lock and Archiving Procedures
NEW QUESTION # 46
An astute monitor discovers that a site is using nebulized albuterol rather than the inhaler provided in the study screening kit for the albuterol challenge. Which is the best response from the Data Manager?
- A. Contact the Ethics Committee
- B. Update the CRF Completion Guidelines and notify all sites of the update
- C. Query the site to enter a Protocol Violation
- D. No response is needed, the problem does not impact data
Answer: C
Explanation:
In this scenario, the site has deviated from the approved study protocol by using a different formulation (nebulized albuterol instead of inhaler). This is considered a protocol deviation or violation, depending on study definitions.
Per GCDMP (Chapter: Data Validation and Cleaning) and ICH E6(R2), Data Managers are responsible for ensuring that all protocol deviations affecting data integrity or subject safety are accurately captured and documented within the clinical database. The appropriate action is to issue a data query prompting the site to record the deviation in the designated section (e.g., "Protocol Deviations" CRF).
Option A: Incorrect - it affects data comparability.
Option B: Escalation to the Ethics Committee is handled by the sponsor, not the Data Manager.
Option C: Updating the CRF guidelines is premature; first, the deviation must be logged and assessed.
Therefore, option D (Query the site to enter a Protocol Violation) is the correct and compliant action.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 - Query Management and Protocol Deviations ICH E6(R2) GCP, Section 4.5 - Compliance with Protocol FDA Guidance for Industry: Oversight of Clinical Investigations - Compliance and Protocol Deviation Reporting
NEW QUESTION # 47
In a study conducted using paper CRFs, a discrepancy is discovered in a CRF to database QC audit. What is the reason why this discrepancy would be considered an audit finding?
- A. Discrepancy not explained by the data handling conventions
- B. Discrepancy not explained by the data quality control audit plan
- C. Discrepancy not explained by the CRF completion guidelines
- D. Discrepancy not explained by the protocol
Answer: A
Explanation:
In a CRF-to-database quality control (QC) audit, auditors compare data recorded on the paper Case Report Form (CRF) with data entered in the electronic database. If discrepancies exist that cannot be explained by documented data handling conventions, they are classified as audit findings.
Per GCDMP (Chapter: Data Quality Assurance and Control), data handling conventions define acceptable data entry practices, transcription rules, and allowable transformations. These conventions ensure that CRF data are consistently interpreted and entered.
If a discrepancy deviates from these established rules, it indicates a process gap or error in data entry, validation, or training. Discrepancies justified by protocol design or CRF guidelines would not constitute findings.
Therefore, option C (Discrepancy not explained by the data handling conventions) correctly identifies the criterion for a true QC audit finding.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.1 - Data Handling Conventions and QC Auditing ICH E6(R2) GCP, Section 5.1 - Quality Management and Documentation of Deviations FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.5 - Data Verification and Audit Findings
NEW QUESTION # 48
During a database audit, it was determined that there were more errors than expected. Who is responsible for assessing the overall impact on the analysis of the data?
- A. Data Manager
- B. Statistician
- C. Quality Auditor
- D. Investigator
Answer: B
Explanation:
The Statistician is responsible for assessing the overall impact of data errors on the analysis and study results.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Quality Assurance and Control) and ICH E9 (Statistical Principles for Clinical Trials), while the Data Manager ensures data accuracy and completeness through cleaning and validation, the Statistician determines whether the observed data discrepancies are statistically significant or if they may affect the validity, power, or interpretability of the study's outcomes.
The Quality Auditor (C) identifies and reports issues but does not quantify analytical impact. The Investigator (D) is responsible for clinical oversight, not statistical assessment. Thus, after a database audit, the Statistician (B) performs a formal evaluation to determine whether the magnitude and nature of the errors could bias results or require reanalysis.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.3 - Data Audit and Impact Assessment ICH E9 - Statistical Principles for Clinical Trials, Section 3.2 - Data Quality and Analysis Impact Assessment FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Validation and Analysis Review
NEW QUESTION # 49
Which of the following tasks would be reasonable during a major upgrade of a clinical data management system?
- A. The ability to access and read the clinical data archive should be tested.
- B. The data archive should be migrated to an offsite database server.
- C. All of the data formats in the archive should be updated to new standards.
- D. All of the case report forms should be pulled and compared to the archive.
Answer: A
Explanation:
During a major system upgrade, it is critical to verify that archived data remain accessible, readable, and intact following the implementation.
According to the GCDMP (Chapter: Database Lock and Archiving), regulatory requirements such as 21 CFR Part 11 and ICH E6(R2) mandate that archived data must remain retrievable in a human-readable format for the duration of retention (often years after study completion).
Therefore, as part of validation and verification testing, organizations must confirm that existing archives can still be accessed using the upgraded system or compatible tools.
Option A: Updating archive formats could alter original data integrity (noncompliant).
Option C: Migration offsite is an IT infrastructure task, not directly tied to the upgrade process.
Option D: Comparing CRFs to archives is unnecessary unless data corruption is suspected.
Hence, option B (testing archive accessibility) is the correct and compliant approach.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Lock and Archiving, Section 5.4 - System Upgrades and Archive Validation ICH E6(R2) GCP, Section 5.5.3 - System Validation and Data Retention FDA 21 CFR Part 11 - Data Archiving, Retention, and Retrieval Requirements
NEW QUESTION # 50
Which is the most important reason for why a data manager would review data before a monitor reviews it?
- A. Data managers have access to programming tools to identify discrepancies.
- B. The GCDMP recommends that data managers review data prior to a monitor's review.
- C. Data can be viewed and discrepancies highlighted prior to a monitor's review.
- D. Data managers write the Data Management Plan that specifies the data cleaning workflow.
Answer: C
Explanation:
The primary reason data managers review data before a monitor's review is to identify and flag discrepancies or inconsistencies so that site monitors can focus their efforts more efficiently during on-site or remote source data verification (SDV).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Validation and Cleaning), proactive data review by data management staff ensures data completeness and accuracy by identifying missing, inconsistent, or out-of-range values. This pre-review helps streamline the monitoring process, reduces the volume of open queries, and enhances data quality.
Option A is true but not the main reason for pre-monitor review. Option C highlights a capability rather than a rationale. Option D is partially correct, but the GCDMP emphasizes process purpose, not prescriptive order. Thus, option B correctly captures the practical and process-oriented reason for early data review-to ensure data are ready and accurate for the monitor's review phase.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.3 - Data Review Timing and Purpose ICH E6(R2) GCP, Section 5.18 - Monitoring and Data Verification Requirements
NEW QUESTION # 51
What significant difference is there in the DM role when utilizing an EDC application?
- A. Metrics generation is required
- B. Tracking of eCRFs is a monitor's responsibility
- C. Data updates are implemented by the sites
- D. Database validation is not required
Answer: C
Explanation:
The most significant difference in the Data Manager's role when using an Electronic Data Capture (EDC) system is that data updates are implemented directly by site personnel (Option A).
According to the GCDMP (Chapter: Electronic Data Capture Systems), EDC technology shifts responsibility for data entry and correction from the sponsor or CRO to the investigator site, enabling real-time data entry and validation. This eliminates the need for double entry or remote data transcription, allowing Data Managers to focus on system validation, query management, and data quality oversight rather than physical data handling.
However, the EDC system still requires full validation (contrary to Option B). Metrics generation (Option C) and CRF tracking (Option D) are important but not unique to EDC-based workflows.
Thus, the correct answer is Option A - Data updates are implemented by the sites, reflecting the most fundamental operational shift introduced by EDC systems.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC) Systems, Section 4.1 - Role of the Data Manager in EDC ICH E6 (R2) GCP, Section 5.5.3 - Electronic Data Entry and Responsibilities FDA 21 CFR Part 11 - Electronic Records and Signatures: Data Entry Responsibilities
NEW QUESTION # 52
The primary reason for system validation is to:
- A. Meet regulatory requirements.
- B. Prove the system being tested works as intended.
- C. Allow a system to be used by its intended users.
- D. Fulfill the validation plan.
Answer: B
Explanation:
The primary purpose of system validation in clinical data management is to demonstrate and document that the computerized system performs as intended-accurately, reliably, and consistently-throughout its lifecycle.
According to the Good Clinical Data Management Practices (GCDMP, Chapter on System Validation) and FDA 21 CFR Part 11, validation ensures that all system functions (e.g., data entry, edit checks, audit trails, security) work as designed, providing data integrity, traceability, and regulatory compliance. The focus is on fitness for intended use, meaning the system reliably produces correct and reproducible results in the context of its operational environment.
While meeting regulatory requirements (option C) and fulfilling a validation plan (option B) are components of the process, they are not the ultimate purpose. The essential goal is ensuring that the system performs as intended, maintaining accuracy and data integrity for clinical trial operations.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Computerized Systems and System Validation, Section 5.2 - Purpose and Scope of System Validation FDA 21 CFR Part 11 - Validation of Computerized Systems for Intended Use ICH E6(R2) GCP, Section 5.5.3 - Computerized System Validation and Data Integrity
NEW QUESTION # 53
Which attribute is NOT a characteristic of a standardized data collection element?
- A. A standard set of values used to respond to a data collection question
- B. A unique set of data storage metadata, including a variable name and data type
- C. A strictly enforced requirement for the positioning of each data element on a case report form
- D. An unambiguous definition for the data element
Answer: C
Explanation:
A standardized data collection element has well-defined metadata, consistent naming conventions, and controlled terminology to ensure uniform data collection and interoperability across studies.
Key attributes, as per GCDMP and CDISC standards, include:
A clear definition of meaning (A)
A controlled set of response values (C)
Metadata specifications like variable names, formats, and data types (D) However, the physical positioning of a data element on a case report form (B) is a matter of form layout design, not a characteristic of data standardization. While consistent form structure aids usability, it is not part of data standardization or metadata management principles.
Hence, option B is correct - form positioning is not a standardized data element attribute.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Standards and Data Integration, Section 4.1 - Data Element Standardization CDISC CDASH Implementation Guide, Section 3.2 - Standardized Data Collection Elements and Metadata ICH E6(R2) GCP, Section 5.5.3 - Data Handling and Standardization
NEW QUESTION # 54
In the transfer of obligations for a double-blind, multi-center trial, a sponsor has maintained the task of creating the randomization schedule. Who at the sponsor company should create the randomization schedule?
- A. The CRO biostatistician
- B. The sponsor's project biostatistician
- C. The sponsor's project statistical programmer
- D. A sponsor's biostatistician not on the project
Answer: D
Explanation:
In a double-blind clinical trial, the randomization schedule must be generated by an independent biostatistician not directly involved in study operations or data management to preserve study blinding and integrity.
According to ICH E9 and the GCDMP (Chapter: Regulatory Requirements and Compliance), randomization generation and blinding must be handled in a way that prevents bias or unintentional unblinding of study personnel. The sponsor's biostatistician not assigned to the project (Option C) is the appropriate person because they have the necessary statistical expertise but remain operationally independent from study execution.
A project biostatistician (Option D) or programmer (Option A) directly involved in data analysis could inadvertently compromise blinding. The CRO biostatistician (Option B) should not perform this function if the sponsor retains randomization responsibility.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Regulatory Requirements and Compliance, Section 6.4 - Randomization and Blinding ICH E9 - Statistical Principles for Clinical Trials, Section 5.4 - Randomization Procedures and Blinding FDA Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, Section 4.3 - Maintaining Blinding Integrity
NEW QUESTION # 55
In an EDC study, an example of an edit check that would be inefficient to run at data entry is a check:
- A. Against a valid list of values.
- B. On the format of a date.
- C. Across visits for consistency.
- D. Against a valid numeric range.
Answer: C
Explanation:
In Electronic Data Capture (EDC) systems, edit checks are categorized based on when and how they are executed - typically immediate (at data entry) or batch (post-entry). Checks that require data from multiple visits or forms are generally inefficient to run at data entry because they depend on information that may not yet exist in the system.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Validation and Cleaning), cross-visit consistency checks - such as comparing baseline and follow-up blood pressure or verifying date order between screening and dosing - should be executed as batch or scheduled validations, not at the point of data entry. Running these complex checks in real time can slow system performance, increase query load unnecessarily, and confuse site users if related data are not yet entered.
Conversely, edit checks against valid ranges, formats, or predefined value lists (options A, C, and D) are simple, local validations ideally performed immediately at data entry to prevent basic errors.
Therefore, cross-visit consistency checks (Option B) are best executed later, making them inefficient for real-time data entry validation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 - Real-Time vs. Batch Edit Checks FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Edit Checks and Data Validation Logic CDISC SDTM Implementation Guide - Section on Temporal Data Consistency Validation
NEW QUESTION # 56
Which of the following data verification checks would most likely be included in a manual or visual data review step?
- A. Checking mandatory fields for missing values
- B. Checking adverse event treatments against concomitant medications
- C. Checking a value against a reference range
- D. Checking an entered value against a valid list of values
Answer: B
Explanation:
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks.
According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding.
For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles
NEW QUESTION # 57
A Data Manager is drafting a report for clinical operations staff for support in responding to questions about milestone-based site payments. Which is the most important information to display?
- A. Milestones met by month, by type
- B. Expected versus actual milestones met to date, by site
- C. Milestones met by month, by site
- D. Milestones included in the last payment by site, by patient
Answer: B
Explanation:
When reporting milestone-based site payment information, the most critical information to include is expected versus actual milestones met to date, by site.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Communication), effective reporting must support operational and financial decision-making by presenting performance indicators in a clear, actionable format. Site payments in clinical studies are typically tied to specific milestones such as subject enrollment, visit completion, or data cleaning achievements.
By comparing expected (planned) versus actual (achieved) milestones per site, the Data Manager provides clinical operations staff with an accurate view of site progress and payment eligibility. This allows for identification of delayed sites, forecasting of upcoming payments, and early intervention for underperforming centers.
While milestone summaries by month or type (options A and B) may be useful for trend analysis, they lack the operational detail required for financial tracking. Milestone data by patient (option D) is overly granular for site-level payment management.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and Communication, Section 6.2 - Data Reporting for Site Performance and Payments ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Communication and Monitoring Reports FDA Guidance for Industry: Oversight of Clinical Investigations - Site Management and Reporting
NEW QUESTION # 58
In a study, data are key entered by one person after which a second person enters the data without knowledge of or seeing the values entered by the first. The second person is notified during entry if an entered value differs from first entry and the second person's decision is retained as the correct value. Which type of entry is being used?
- A. Manual review
- B. Single entry
- C. Third-party compare
- D. Blind verification
Answer: D
Explanation:
The described process is Blind Verification, also known as double data entry with blind verification. In this method, two independent operators enter the same data. The second operator is blinded to the first entry to avoid bias. When discrepancies arise, the system flags them for review, and the second entry (or an adjudicated value) is retained as the correct one.
According to GCDMP (Chapter: Data Entry and Data Tracking), blind double data entry is used primarily in paper-based studies to minimize transcription errors and ensure data accuracy.
Single entry (D): Only one operator enters data.
Manual review (B): Involves post-entry checking, not during entry.
Third-party compare (C): Used for reconciling external data sources, not CRF data.
Hence, option A (Blind verification) is the correct and CCDM-defined process.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Entry and Data Tracking, Section 5.1 - Double Data Entry and Verification Methods ICH E6(R2) GCP, Section 5.5.3 - Data Entry and Verification Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Accuracy and Verification
NEW QUESTION # 59
What are the key deliverables for User Acceptance Testing?
- A. eCRF Completion Guidelines
- B. Test Plan/Script/Results
- C. Training
- D. Project Plan
Answer: B
Explanation:
The key deliverables for User Acceptance Testing (UAT) are the Test Plan, Test Scripts, and Test Results.
According to the GCDMP (Chapter: Database Design and Validation), UAT is the final validation step before a clinical database is released for production. It confirms that the system performs according to user requirements and protocol specifications.
The deliverables include:
UAT Test Plan: Defines testing objectives, scope, acceptance criteria, and responsibilities.
UAT Test Scripts: Provide step-by-step instructions for testing database functionality, edit checks, and workflows.
UAT Test Results: Document actual test outcomes versus expected outcomes, including any deviations and their resolutions.
These deliverables form part of the system validation documentation required under FDA 21 CFR Part 11 and ICH E6 (R2) to demonstrate that the database has been properly validated.
Project Plans (option A) and Training (option B) occur in earlier phases, while eCRF Completion Guidelines (option D) support site data entry, not system validation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation, Section 5.3 - User Acceptance Testing Deliverables FDA 21 CFR Part 11 - Validation Documentation Requirements ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - System Validation Records
NEW QUESTION # 60
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
- A. Reviewing data listings for illogical changes in range of motion between visits
- B. Comparison to the measurement from the previous visit
- C. Programmed edit checks to detect out-of-range values upon data entry
- D. Independent assessment by a second physical therapist during the visit
Answer: D
Explanation:
In this scenario, the variable of interest-range of motion (ROM)-is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.
Other options, while valuable, address only data consistency or plausibility after collection:
Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.
Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.
The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 - Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 - Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 - Quality Control of Clinician-Assessed Data SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures
NEW QUESTION # 61
Which of the following roles commonly requires data entry and update privileges in an EDC application used in a clinical study?
- A. Study Statistician
- B. Site Study Coordinator
- C. Clinical Study Monitor
- D. EDC System Administrator
Answer: B
Explanation:
In an EDC system, Site Study Coordinators are typically responsible for data entry and updates, as they are the site-level personnel who record subject data from source documents into the electronic CRFs (eCRFs).
The Good Clinical Data Management Practices (GCDMP, Chapter: EDC Systems) outlines that data entry and modification privileges should only be granted to qualified site personnel who have completed EDC system training and are listed on the study delegation log. These users directly handle patient-level data entry and correction.
In contrast:
Clinical Study Monitors (B) review and verify data but do not enter or modify it.
EDC System Administrators (C) manage user access and configuration settings, not study data.
Study Statisticians (D) work with extracted, cleaned datasets but never have data modification privileges.
Thus, option A (Site Study Coordinator) correctly identifies the role with authorized data entry and update privileges.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 - User Roles and Access Permissions ICH E6(R2) GCP, Section 4.1 - Investigator Responsibilities for Data Accuracy FDA 21 CFR Part 11 - User Access and Accountability in Electronic Systems
NEW QUESTION # 62
At a cross-functional study team meeting, a statistician suggests collecting blood gases electronically through the existing continuous hemodynamic monitoring system at sites rather than having a person record the values every five minutes during the study procedure. Assuming that sending, receiving, and integrating these data are possible, what is the best response?
- A. Manual recording is preferred because the sites may forget to turn on the machine and lose data
- B. Manual recording is preferred because healthcare devices are not validated to 21 CFR Part 11 standards
- C. Electronic acquisition is preferable because more data points can be acquired
- D. Electronic acquisition is preferable because the chance for human error is removed
Answer: C
Explanation:
Assuming the data transfer, integration, and validation processes are properly controlled and compliant, electronic acquisition of clinical data from medical devices is preferred because it allows more frequent and accurate data collection, leading to higher data resolution and integrity.
Per the GCDMP (Chapter: Technology and Data Integration), automated data collection minimizes manual transcription and reduces latency in data capture, ensuring both efficiency and completeness. While manual processes introduce human transcription errors and limit frequency, continuous electronic data capture can record thousands of accurate, time-stamped measurements, improving the study's analytical power.
However, option D slightly overstates the case - human error is reduced, not entirely eliminated, since setup, calibration, and integration still involve human oversight. Therefore, option C is the best and most precise response, emphasizing the advantage of more robust and complete data capture.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Technology and Data Integration, Section 5.4 - Automated Data Acquisition and Validation ICH E6(R2) GCP, Section 5.5.3 - Validation of Computerized Systems and Electronic Data Sources FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - Direct Data Capture from Instruments and Devices
NEW QUESTION # 63
Which is the MOST appropriate flow for EDC set-up and implementation?
- A. Database created, Subjects enrolled, Database tested, Sites trained, Database released
- B. CRF "wire-frames" created, CRFs reviewed, CRFs printed, CRFs distributed to sites
- C. Database created, Database tested, Sites trained, Protocol finalized, Database released
- D. Protocol finalized, Database created, Edit Checks created, Database tested, Sites trained
Answer: D
Explanation:
The correct and compliant sequence for EDC system setup and implementation begins only after the study protocol is finalized, as all case report form (CRF) designs, database structures, and validation rules derive directly from the finalized protocol.
According to GCDMP (Chapter: EDC Systems Implementation), the proper order is:
Protocol finalized - defines endpoints and data requirements.
Database created - built according to the protocol and CRFs.
Edit checks created - programmed to validate data entry accuracy.
Database tested (UAT) - ensures functionality, integrity, and compliance.
Sites trained and system released - only then can data entry begin.
Option B follows this logical and regulatory-compliant sequence. Other options (A, C, D) are either paper-based workflows or violate GCP-compliant timelines (e.g., enrolling subjects before database validation).
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Electronic Data Capture (EDC) Systems, Section 5.2 - System Setup and Implementation Flow ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation and User Training Before Use FDA 21 CFR Part 11 - Validation and System Release Requirements
NEW QUESTION # 64
......
CCDM dumps Exam Material with 152 Questions: https://realdumps.prep4sures.top/CCDM-real-sheets.html